CONAR P FITTON
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
- Where
- KENNER, LA
- NPI
- 1316182744
- Received
- $954,680 in 1,065 records, 2019 to 2025
- As principal investigator
- $680,267 of research payments to others in 61 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 289 | $296,604 |
| 2024 | General payment | 232 | $215,786 |
| 2023 | General payment | 133 | $95,481 |
| 2022 | General payment | 87 | $91,930 |
| 2021 | General payment | 139 | $123,172 |
| 2020 | General payment | 45 | $14,770 |
| 2019 | General payment | 140 | $116,933 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 723 | $606,938 | 2019–2025 |
| GENZYME CORPORATION | 90 | $149,693 | 2023–2025 |
| Novo Nordisk Inc | 51 | $78,361 | 2025 |
| Phathom Pharmaceuticals, Inc. | 84 | $63,947 | 2024–2025 |
| Ipsen Biopharmaceuticals, Inc | 18 | $23,571 | 2025 |
| ABBVIE INC. | 57 | $22,969 | 2019–2025 |
| Regeneron Healthcare Solutions, Inc. | 12 | $8,257 | 2024–2025 |
| RedHill Biopharma Inc. | 9 | $176 | 2021–2023 |
| Medtronic, Inc. | 2 | $165 | 2021 |
| Covidien LP | 2 | $154 | 2020 |
| Exact Sciences Corporation | 1 | $119 | 2024 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $117 | 2019–2025 |
| Ethicon US, LLC | 1 | $92 | 2021 |
| IRONWOOD PHARMACEUTICALS, INC | 4 | $54 | 2019–2020 |
| Allergan, Inc. | 1 | $20 | 2019 |
| Boston Scientific Corporation | 1 | $14 | 2021 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 | 2023 |
| KCI USA, Inc. | 1 | $11 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 119 | $495,729 |
| Compensation for serving as faculty or as a speaker for a medical education program | 52 | $216,287 |
| Travel and Lodging | 409 | $104,607 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 38 | $103,000 |
| Food and Beverage | 438 | $23,618 |
| Consulting Fee | 5 | $11,360 |
| Education | 4 | $77 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $6,355 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $5,115 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $237 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $195 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $195 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $119 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $71 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $71 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-16 | Novo Nordisk Inc | $26 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $8,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $285 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $170 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $144 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $19 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $6,975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $273 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $134 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $104 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $81 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-02 | Novo Nordisk Inc | $5,735 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-12-02 | Novo Nordisk Inc | $273 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-02 | Novo Nordisk Inc | $268 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-02 | Novo Nordisk Inc | $212 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-02 | Novo Nordisk Inc | $53 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $5,425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $105 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $99 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-18 | Novo Nordisk Inc | $5,115 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-18 | Novo Nordisk Inc | $233 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-18 | Novo Nordisk Inc | $87 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-14 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | Novo Nordisk Inc | $5,425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-10 | Novo Nordisk Inc | $95 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-10 | Novo Nordisk Inc | $29 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-08 | Novo Nordisk Inc | $28 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $6,665 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $1,002 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $784 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $404 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $95 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-11-05 | Phathom Pharmaceuticals, Inc. | $287 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-11-05 | Phathom Pharmaceuticals, Inc. | $7 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $6,355 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $519 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $417 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $175 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $17 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $324 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $114 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-17 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-17 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $6,975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $568 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $350 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $135 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $75 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $9,098 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $570 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $428 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $291 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $221 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-08 | GENZYME CORPORATION | $3,839 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-08 | Phathom Pharmaceuticals, Inc. | $2,580 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-10-08 | GENZYME CORPORATION | $124 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-01 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-30 | Phathom Pharmaceuticals, Inc. | $121 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-09-25 | GENZYME CORPORATION | $8,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-25 | GENZYME CORPORATION | $470 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-25 | GENZYME CORPORATION | $297 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-25 | GENZYME CORPORATION | $138 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-25 | Ipsen Biopharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-24 | Ipsen Biopharmaceuticals, Inc | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-24 | Ipsen Biopharmaceuticals, Inc | $846 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-24 | Ipsen Biopharmaceuticals, Inc | $342 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-24 | Ipsen Biopharmaceuticals, Inc | $201 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-08-13 | GENZYME CORPORATION | $119 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-16 | Phathom Pharmaceuticals, Inc. | $117 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-07-16 | Phathom Pharmaceuticals, Inc. | $103 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-06-30 | GENZYME CORPORATION | $8,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-30 | GENZYME CORPORATION | $466 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-30 | GENZYME CORPORATION | $124 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-25 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $716 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $230 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $120 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $112 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $298 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-10 | Ipsen Biopharmaceuticals, Inc | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-06-10 | Ipsen Biopharmaceuticals, Inc | $910 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-06-10 | Ipsen Biopharmaceuticals, Inc | $165 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $215 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $206 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $199 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-04 | Phathom Pharmaceuticals, Inc. | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-06-03 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-29 | Ipsen Biopharmaceuticals, Inc | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-29 | Ipsen Biopharmaceuticals, Inc | $487 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-29 | Ipsen Biopharmaceuticals, Inc | $287 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-29 | Ipsen Biopharmaceuticals, Inc | $122 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-29 | Phathom Pharmaceuticals, Inc. | $21 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-28 | Phathom Pharmaceuticals, Inc. | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-28 | Phathom Pharmaceuticals, Inc. | $1,290 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-27 | Phathom Pharmaceuticals, Inc. | $107 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-21 | Phathom Pharmaceuticals, Inc. | $23 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-21 | Phathom Pharmaceuticals, Inc. | $11 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $405 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $247 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $122 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $101 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $7 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-14 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-05-12 | Ipsen Biopharmaceuticals, Inc | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-07 | Phathom Pharmaceuticals, Inc. | $66 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-06 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $435 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-06 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-06 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-06 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-30 | Phathom Pharmaceuticals, Inc. | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-04-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-24 | GENZYME CORPORATION | $7,329 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-24 | GENZYME CORPORATION | $671 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-24 | GENZYME CORPORATION | $304 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-24 | GENZYME CORPORATION | $73 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-23 | Phathom Pharmaceuticals, Inc. | $77 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-04-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $539 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $242 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $121 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $105 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-21 | Phathom Pharmaceuticals, Inc. | $14 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $204 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $124 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $8,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | Phathom Pharmaceuticals, Inc. | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $482 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $272 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $157 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $121 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $47 | Food and Beverage | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $24 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $292 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $112 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $8 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $164 | Travel and Lodging | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 |
The latest 200 records of 1,065.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-04 | ABBVIE INC. | Tandem Intermediate Llc | $6,000 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treate | 2025 |
| 2025-08-20 | ABBVIE INC. | Tandem Intermediate Llc | $2,050 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treate | 2025 |
| 2025-07-16 | AstraZeneca Pharmaceuticals LP | Tandem Clinical Research | $21,762 | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2025 |
| 2025-07-02 | ABBVIE INC. | Tandem Intermediate Llc | $14,500 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treate | 2025 |
| 2024-12-18 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $3,500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-12-18 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $25,310 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-11-14 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $15,186 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-11-14 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $3,500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-11-12 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $750 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-11-12 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $1,300 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $2,500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $20,248 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $80 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-29 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-10-03 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $2,344 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-30 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $4,900 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-30 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $20,248 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-19 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $3,000 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-09-13 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $3,770 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-28 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $1,400 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-16 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $5,492 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-16 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-14 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $500 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-08-01 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $80 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $30,372 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-31 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $650 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Bausch Health US, LLC | Tandem Clinical Research GI, LLC | $3,000 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $20,248 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-19 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI - HOUMA | $2,100 | A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegopraza | 2024 |
| 2024-07-17 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $10,009 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-24 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $500 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-24 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $500 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-02 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $200 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-05-02 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $200 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-15 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $1,016 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $2,000 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $2,598 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $18,900 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $2,000 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $2,598 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-04-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $18,900 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-14 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $4,553 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-14 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $4,553 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $750 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-03-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $750 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-02-22 | Bausch Health US, LLC | Tandem Clinical Research GI, LLC | $1,850 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-02-21 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $7,242 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-02-21 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $7,242 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-02-08 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $1,565 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-02-08 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $174 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-01-31 | AstraZeneca Pharmaceuticals LP | Tandem Clinical Research GI, LLC | $33,334 | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2024 |
| 2024-01-15 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $5,301 | A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroe | 2024 |
| 2024-01-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $261 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-01-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $9,060 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-01-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $9,060 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2024-01-04 | Braintree Laboratories, Inc. | TANDEM CLINICAL RESEARCH GI LLC | $261 | A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patie | 2024 |
| 2023-11-15 | AstraZeneca Pharmaceuticals LP | Tandem Clinical Research GI, LLC | $6,767 | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2023 |
| 2023-04-28 | AstraZeneca Pharmaceuticals LP | Tandem Clinical Research | $306,220 | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kenner, LA, county Jefferson Parish, LA, state Louisiana; placed by its city name.
| Measure | Place (city or town) Kenner, LA | County Jefferson Parish, LA | State Louisiana |
|---|---|---|---|
| Population B01003 | 64,904 | 430,920 | 4,611,961 |
| Population, 2020 census P1 | 66,448 | 440,781 | 4,657,757 |
| Median age B01002 | 39.3 | 40.0 | 38.0 |
| Under 18 B01001 | 23.6% | 22.4% | 23.5% |
| 65 and over B01001 | 19.2% | 18.6% | 16.7% |
| Households B11001 | 25,557 | 177,003 | 1,804,780 |
| Foreign born B05002 | 21.1% | 14.6% | 4.9% |
| Median household income B19013 | $64,020 | $65,252 | $60,756 |
| Median family income B19113 | $83,142 | $84,920 | $79,407 |
| Per capita income B19301 | $36,508 | $37,862 | $35,038 |
| Poverty rate B17001 | 15.4% | 16.6% | 18.9% |
| Unemployment rate B23025 | 6.6% | 6.2% | 6.3% |
| Civilian labor force B23025 | 32,656 | 217,475 | 2,148,164 |
| Mean commute (minutes) B08013 | 25.3 | 24.3 | 25.7 |
| Bachelor's degree or higher B15003 | 29.1% | 30.5% | 27.0% |
| Housing units B25001 | 27,908 | 194,418 | 2,108,902 |
| Owner-occupied B25003 | 63.1% | 62.6% | 67.4% |
| Renters B25003 | 36.9% | 37.4% | 32.6% |
| Median home value B25077 | $246,300 | $251,400 | $216,500 |
| Median gross rent B25064 | $1,179 | $1,190 | $1,064 |
| White, not Hispanic B03002 | 42.4% | 47.2% | 55.7% |
| Black B03002 | 17.0% | 25.1% | 30.5% |
| Hispanic or Latino B03002 | 29.5% | 18.9% | 7.2% |
| Asian B03002 | 4.6% | 4.2% | 1.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.4% |
Economy now FRED unemployment 4.0% in Sep 2026 (4.2% a year earlier); per capita personal income $64,103 in 2025, up 28% in five years (+2.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kenner, LA.
Comments